ReNeuron Group PLC RENE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX 3.45
- Day Range
- GBX 3.28–3.50
- 52-Week Range
- GBX 3.28–11.50
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 192.96 Mil
- Volume/Avg
- 177,620 / 405,639
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.75
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 32
- Website
- https://www.reneuron.com
Valuation
|
Metric
|
RENE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.80 |
Price/Sales | 7.75 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RENE
|
|---|---|
Quick Ratio | 1.51 |
Current Ratio | 1.51 |
Interest Coverage | −347.56 |
Quick Ratio
RENE
Profitability
|
Metric
|
RENE
|
|---|---|
Return on Assets (Normalized) | −45.11% |
Return on Equity (Normalized) | −92.62% |
Return on Invested Capital (Normalized) | −88.23% |
Return on Assets
RENE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dqnvdnwml | Nxtr | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bvwzxtcp | Fjzbmr | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mdkrfyq | Bcyznwg | $97.8 Bil | |
MRNA
| Moderna Inc | Nhvdxryyp | Ttr | $41.3 Bil | |
ARGX
| argenx SE ADR | Lsddydrsp | Lqyy | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nvppgggk | Bzjcq | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wjcymjgd | Dkkzhkd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kpjwxlt | Prywtlt | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Dylfdfmnv | Hpcmgv | $12.5 Bil | |
INCY
| Incyte Corp | Khbpsmk | Cxwdjb | $11.6 Bil |